Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1 billion a year from 2027, reversing years of growth made possible ...
The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot. The new vaccine ...
Moderna (MRNA) shares reached a new 52-week high on Thursday as the COVID-19 vaccine maker extended its recent gains to record a nearly 84% jump for this year alone after multiple years of consecutive ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use previously issued a positive opinion recommending marketing authorization of Moderna’s new COVID-19 vaccine, mNEXSPIKE ...
Here's your look at the Zlín City: Arch Moderna announcement trailer for this upcoming cozy, historically inspired city-builder. Join developer Polyperfect for a behind-the-scenes look at the creation ...
CAMBRIDGE, MA - Moderna, Inc. (NASDAQ:MRNA) has dosed the first patient in a Phase 1/2 study of mRNA-2808, its investigational mRNA-based T-cell engager therapy for relapsed or refractory multiple ...
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its financial performance and a recent clinical setback overshadowed an ...
The cease-fire talks in Egypt showed that with pressure on Hamas and Israel, seemingly huge impediments could be overcome or set aside. By Adam Rasgon David M. Halbfinger Natan Odenheimer Ronen ...
Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...
Moderna is cutting its workforce by 10% to align costs with business demands, targeting fewer than 5,000 employees by year-end. The company aims to reduce annual operating expenses by $1.5 billion by ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results